- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02078765
Nocturnal Blood Pressure and Hypertension - Central and Peripheral 24-h Blood Pressure. (HOSA)
Nocturnal Blood Pressure in Hypertension, Obstructive Sleep Apnea and Healthy Subjects - Central and Peripheral 24-h Blood Pressure
A new study have shown that high night time blood pressure (BP) and/or non-dipping (lack of fall in BP during night time) is a strong predictor for the risk of cardiovascular disease and mortality in patients with hypertension. Three factors seem to affect the night time BP: chronic kidney disease, obstructive sleep apnea (OSA) and the way ambulatory blood pressure is monitored.
Hypothesis:
Central 24-h blood pressure monitoring is a better way of monitoring blood pressure than conventional peripheral monitoring.
In hypertension, chronic kidney disease and obstructive sleep apnea (OSA) the night time blood pressure is elevated, and is OSA the elevation is correlated to the severity of OSA.
In OSA the kidneys handling of salt and water is disturbed. In OSA there is disturbances in hormonal balance.
Study Overview
Status
Detailed Description
75 patients with hypertension and chronic kidney disease (CKD I-II) and 75 healthy subjects is examined with both central and peripheral 24 hours blood pressure monitoring, 1 night home polygraphy to determine whether the subject has obstructive sleep apnea (OSA), and if so the degree (apnea hypopnea index, AHI), blood and urine samples to determine levels of urine aquaporine2 (u-AQP2), urine endothelial sodium channel (u-EnaC), plasma renin concentration (PRC), plasma angiotensin II (p-AngII), plasma aldosterone (p-aldosterone), plasma vasopressin (p-AVP) and plasma endothelin (p-endothelin).
Hypothesis:
Central 24-h BP monitoring provides another measure of daily fluctuations in blood pressure than peripheral 24-h BP monitoring, because this measurement is painless and does not interfere with activities in the daytime or night-time sleep.
In hypertension, chronic kidney disease and OSA the decease in nocturnal BP is lower than i healthy subjects.
In OSA the decrease in the nocturnal BP is inversely correlated with the severity of OSA.
In OSA is the renal tubular absorption of water and sodium abnormal with increased tubular absorption of water with AQP2 and of sodium by ENAC.
In OSA, there is increased activity of the renin-angiotensin-aldosterone system, increased endothelin in plasma and increased vasopressin in plasma.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Holstebro, Denmark, 7500
- Department of Medical Research and Medicine, Holstebro Regional Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Group 1: 75 patients with hypertension, recruited from another study in the Holstebro Area, contacted by letter.
Group 2: healthy subjects are recruited though posters in public and private companies as well as advertising in local media.
Description
Group 1:
Inclusion Criteria:
- Chronic kidney disease (CKD stage I and II), estimated glomerule filtration rate (eGFR) 60-90 ml/min/1.73 m2 or eGFR> 90 ml/min/1.73 m2 and proteinuria or other signs of kidney damage.
- Hypertension (BP by ambulatory or home blood pressure> 135/85 mmHg, or consultation blood pressure> 140/90 mmHg).
- Both men and women
- 55-70 years
- A completed consent form
Exclusion Criteria:
- Lack of desire to participate
- In the treatment of OSA
- Malignant disease
- Abuse of drugs or alcohol
- Pregnant and breastfeeding
- Incompensated heart failure
- Atrial fibrillation
- Liver disease (Alanine aminotransferase (ALT)> 200)
- Severe chronic obstructive pulmonary disease (COPD) (Forced expiratory volume in 1 second <50% predicted)
- eGFR <60 ml/min/1.73 m2
- Blood pressure difference between the right and left arm> 10/10 mmHg
Group 2 - Healthy subjects
Inclusion Criteria:
- Healthy subjects men and women
- age 55 - 70 years
- Body mass index within the normal range, between 18.5 to 25.0 kg/m2
Exclusion Criteria:
Arterial hypertension, ambulatory blood pressure> 130 mmHg systolic and / or 80 mmHg diastolic.
- a history or clinical signs of cardial, pulmonary, hepato, renal, endocrine, cerebral or neoplastic disorders
- Alcohol abuse, ie. > 14 drinks / week for women and> 21/uge for men
- Substance abuse
- Medical treatment apart from oral contraceptives
- Smoking
- Pregnancy or breastfeeding
- Lack of desire to participate
- Clinically significant, discrepant results of blood or urine sample at inclusion study (B-hemoglobin and B-White blood cell count, p-sodium, p-potassium, p-creatinine, p-ALT, p-bilirubin , p-Alkaline phosphatase, p-cholesterol, p-albumin or b-glucose and urine for hematuria, albuminuria or glucosuria)
- Clinically significant variations in the electrocardiogram
- Blood Donation for the past month preceding the day on the first attempt sequence
- Blood pressure difference between the right and left arm> 10/10 mmHg.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
hypertension
75 patients with hypertension and chronic kidney disease (CKD stage I-II)
|
|
healthy subjects
75 healthy subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
decrease in central systolic blood pressure at night
Time Frame: < 24 hours
|
The difference in the decrease in systolic BP at night by peripheral 24-h BP between patients with hypertension and healthy subjects.
|
< 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
decrease in central systolic blood pressure at night
Time Frame: < 24 hours
|
The difference in the decrease in systolic BP at night by the central 24-h BP between patients with hypertension and healthy subjects.
|
< 24 hours
|
|
difference i blood pressure levels throughout the day
Time Frame: < 24 hours
|
The difference in systolic blood pressure and diastolic blood pressure throughout the day, in the daytime and in nighttime between peripheral 24-h and central 24-h monitoring in both patients and healthy.
|
< 24 hours
|
|
The correlation between the decrease in nighttime BP on one side and severity of OSA and BP in the daytime on the other.
Time Frame: < 24 hours
|
The correlation between the decrease in nighttime BP on one side and severity of OSA and BP in the daytime on the other.
|
< 24 hours
|
|
u-AQP2 and u-ENac
Time Frame: 24 hours
|
In 24-h urine samples
|
24 hours
|
|
PRC, p-AngII, p-aldosterone, p-AVP, p-endothelin
Time Frame: < 1 hour
|
blood samples
|
< 1 hour
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Urologic Diseases
- Renal Insufficiency
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Hypertension
- Kidney Diseases
- Renal Insufficiency, Chronic
- Apnea
Other Study ID Numbers
- BGH-2-2013
- M-2013-303-13 (Other Identifier: The Regional Committee of health Reseach Ethics)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil